Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220097 | 0.73 | CA2 (0.46) | CA2ALDH1A1TDP1CYP2C19CA1 | |
| SCHEMBL108864 | 0.71 | CA2 (0.61) | CA2ALDH1A1TDP1CYP2C19CA1 | |
| SCHEMBL11496244 | 0.67 | ALDH1A1 (0.48) | CA2ALDH1A1TDP1CYP2C19CA1 | |
| SCHEMBL31346305 | 0.66 | CA2 (0.55) | CA2ALDH1A1TDP1CYP2C19CA1 | |
| SCHEMBL5493645 | 0.65 | CA2 (0.42) | CA2ALDH1A1TDP1CYP2C19CA1 | |
| SCHEMBL25404425 | 0.64 | — | — | |
| 2-Oxoisohexanoate SCHEMBL18302256 | 0.64 | CA2 (0.52) | CA2ALDH1A1TDP1CYP2C19CA1 | |
| 2-Oxoisohexanoate SCHEMBL43491 | 0.64 | — | — | |
| SCHEMBL93309 | 0.64 | — | — | |
| 3-Methylbutanoic Acid SCHEMBL8572664 | 0.64 | CA2 (0.88) | CA2ALDH1A1TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | CA2 1760/4885ALDH1A1 2269/4885TDP1 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.